A Professional & Personal Networking Site for Cardiologists Worldwide
RE-LY Subanalysis Suggests Similar Benefit, Less Bleeding With Dabigatran in AF Patients With Prior Stroke or TIA
March 3, 2010 (San Antonio, Texas) — Results of a subanalysis from the Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin,
Compared With Dabigatran (RE-LY) trial comparing dabigatran with
warfarin show that, consistent with the overall trial results,
dabigatran was noninferior to warfarin with less major hemorrhages,
particularly intracerebral hemorrhages, in patients with a prior stroke
or transient ischemic attack (TIA).
Among the 3623 patients with these prior events, constituting about 20% of
the overall study population in RE-LY, "cerebral hemorrhage on warfarin
was higher than in patients without prior TIA or stroke, and this was
not the case with dabigatran," Hans-Christoph Diener, MD, PhD, from the
Department of Neurology at University Hospital Essen in Germany, told
delegates here.
More at Medscape
